TL;DR
Personalized cancer spheroids represent a promising approach linking experimental oncology with precision medicine research, with potential applications in individualized drug testing and treatment optimization.
Systematic identification and validation of novel co-targeting cell surface receptors, such as G protein-coupled receptors (GPCRs), characterized by high tumor relevance and rapid internalization, may improve tumor coverage and drug uptake in therapy-resistant subpopulations.
The development and drug resistance of breast cancer are closely associated with the heterogeneity of the tumor microenvironment (TME). Immunosuppressive cells, activated matrix components, abnormal vascular networks, and metabolic reprogramming within the TME collectively create a niche that promotes tumor survival. D...
Lung cancer is the leading cause of cancer death, characterized by high mortality rates, tumor adaptation and heterogeneity, and immune evasion mechanisms. Despite recent advancements in chemotherapy, radiation, and surgery, survival rates for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) remain...
This framework integrates evidence level, disease stage, biomarker reliability and patient tolerance into treatment selection for TNBC precision therapy and distinguish them from maturing or exploratory strategies such as pathway-directed therapy, epigenetic modulation, anti-vascular combinations, regulated cell-death...
Triple negative breast cancer (TNBC) is the most fatal subtype of breast cancer. Cytotoxic chemotherapy and immune therapy remain the only available therapeutic strategies for treatment, but unfortunately, patients frequently develop drug-resistance. Drug resistance towards chemotherapeutic agents is a major obstacle f...
Abstract Antibody–drug conjugates (ADCs) have become a major therapeutic class in breast cancer, but their clinical performance cannot be predicted by antigen expression alone. This review uses therapeutic-window engineering as a unifying framework to connect ADC molecular architecture with tumor heterogeneity, clinica...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
